Related Experiment Video

Updated: Apr 11, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.5K

Ramucirumab as second-line treatment for patients with metastatic esophagogastric adenocarcinoma

Ralf-Dieter Hofheinz1, Sylvie Lorenzen

  • 1University Hospital Mannheim, Ruprecht Karls University Heidelberg, Mannheim, Germany.

Expert Review of Anticancer Therapy
|June 3, 2015
PubMed

Insights

Ramucirumab, a monoclonal antibody, significantly improved overall survival in patients with metastatic esophagogastric adenocarcinoma. This targeted therapy shows promise in both monotherapy and combination treatments for advanced gastric cancer.

Area of Science:

  • Oncology
  • Immunotherapy
  • Molecular Biology

Background:

  • Ramucirumab is a fully humanized monoclonal antibody that targets the extracellular domain of Vascular Endothelial Growth Factor (VEGF) receptor 2.
  • It functions by inhibiting ligand binding and subsequent pathway activation in endothelial cells, crucial for tumor angiogenesis.

Purpose of the Study:

  • To evaluate the efficacy of ramucirumab in patients with pretreated metastatic esophagogastric adenocarcinoma.
  • To assess ramucirumab's role in prolonging overall survival as both monotherapy and in combination with paclitaxel.

Main Methods:

  • Two pivotal, placebo-controlled Phase III trials (REGARD and RAINBOW) were conducted.
  • Patient populations included those with pretreated metastatic esophagogastric adenocarcinoma.

Main Results:

  • Ramucirumab demonstrated significant clinical activity, prolonging overall survival in both monotherapy (REGARD) and combination (RAINBOW) arms.
  • These findings support its efficacy in advanced gastric cancer treatment.

Conclusions:

  • Ramucirumab is an effective targeted therapy for metastatic esophagogastric adenocarcinoma, improving survival outcomes.
  • Ongoing research (RAINFALL trial) is investigating its first-line treatment potential in combination regimens.
Keywords:
anti-angiogenic treatmentgastroesophageal cancerpaclitaxelramucirumabsecond-line therapy

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

6.1K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

Related Concept Videos

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
2.2K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
1.6K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
675
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
660